immunodeficiencies

Quantitation of these cell types is commonly used to evaluate patients with primary or secondary immunodeficiencies, those who have undergone bone marrow transplantation, and to monitor some solid organ transplant patients.

Immunology Lab 2010

Reduced-intensity transplants for patients with sickle cell disease, thalassemia, immunodeficiencies, HLH.

Our Approach to BMT 2010

In-utero hematopoietic stem cell transplantations are a promising approach for the treatment of selected congenital immunodeficiency disorders (i.e. severe combined immunodeficiencies, chronic granulomatous disease, hyperIgM syndrome and others) and hemoglobinopathies (i.e. sickle cell disease and thalassemia).

In Utero Stem Cell Transplantation 2010

Patients receiving transplants suffer from hematological or non-hematological malignancies, myelodysplastic syndromes, hematological congenital disorders, aplastic anemia, inborn errors of metabolism, or congenital immunodeficiencies.

Stem Cell Lab 2010

Allogeneic transplants with HLA-matched sibling donors for patients with leukemias, hematologic disorders, blood and marrow failure states, metabolic diseases and immunodeficiencies.

Our Approach to BMT 2010

-- Safety and effectiveness in infants with chronic gastrointestinal disorders, or with known primary or secondary immunodeficiencies, have not been evaluated.

GlaxoSmithKline On FDA's Rotavirus Vaccine Concerns 2010

-- Safety and effectiveness in infants with chronic gastrointestinal disorders, or with known primary or secondary immunodeficiencies, have not been evaluated.

GlaxoSmithKline On FDA's Rotavirus Vaccine Concerns 2010

-- Safety and effectiveness in infants with chronic gastrointestinal disorders, or with known primary or secondary immunodeficiencies, have not been evaluated.

GlaxoSmithKline On FDA's Rotavirus Vaccine Concerns GlaxoSmithKline statement 2010

The Merck Manual (first published in 1899, now available in a Home Edition) warns individuals with B and/or T cell immunodeficiencies to avoid live-virus vaccines (the main ingredient in ones produced by Novartis, GlaxoSmithKline, and perhaps others) due to the risk of severe or fatal infections.

Early and Current Fears about Vaccine Dangers 2009

The Merck Manual (first published in 1899, now available in a Home Edition) warns individuals with B and/or T cell immunodeficiencies to avoid live-virus vaccines (the main ingredient in ones produced by Novartis, GlaxoSmithKline, and perhaps others) due to the risk of severe or fatal infections.

Printing: Early and Current Fears about Vaccine Dangers 2009